Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
News|Articles|May 29, 2024
Psychedelics Safety Poll
Author(s)Psychiatric Times Editors
Answer a quick question on psychedelics!
Advertisement
How do you perceive the safety profile of psychedelics compared with traditional psychiatric medications?
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Burnout, Gratitude, and the Value of Staying Current: On the Mind of Gus Alva, MD, DFAPA
2
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
3
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
4
Neflamapimod for Dementia With Lewy Bodies Misses End Point, Subgroup Signal Emerges
5